Literature DB >> 3203706

Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.

I De Lepeleire1, A Van Hecken, R Verbesselt, G Kaiser, A Barner, I Holmes, P J De Schepper.   

Abstract

Single oral doses of 10 mg converting enzyme inhibitor benazepril (CGS 14824A) and 40 mg furosemide were administered to 12 healthy male volunteers either separately or concomitantly. The pharmacokinetic parameters of benazepril were not influenced by coadministration of furosemide. Urinary excretion of total furosemide was significantly reduced by 10 to 20% in the presence of benazepril. This effect was considered clinically insignificant. Erect blood pressure decreased and pulse rate increased only during concomitant treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203706     DOI: 10.1007/bf01046703

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Measurement of furosemide by high-performance liquid chromatography.

Authors:  S E Swezey; P J Meffin; T F Blaschke
Journal:  J Chromatogr       Date:  1979-07-01

2.  Comparison of different methods for decision-making in bioequivalence assessment.

Authors:  D Mandallaz; J Mau
Journal:  Biometrics       Date:  1981-06       Impact factor: 2.571

3.  An aid to decision-making in bioequivalence assessment.

Authors:  H Fluehler; J Hirtz; H A Moser
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

4.  Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.

Authors:  A Rakhit; G M Kochak; V Tipnis; M E Hurley
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

5.  Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers.

Authors:  M D Schaller; J Nussberger; B Waeber; J P Bussien; G A Turini; H Brunner; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.

Authors:  R A Lewis; K M Baker; C R Ayers; B A Weaver; M R Lehman
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

7.  The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.

Authors:  F Andreasen; C K Christensen; F K Jakobsen; C E Mogensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-09

8.  Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatography-mass spectrometry.

Authors:  G Kaiser; R Ackermann; W Dieterle; J P Dubois
Journal:  J Chromatogr       Date:  1987-08-07

9.  Implications of intraindividual variability in bioavailability studies of furosemide.

Authors:  A Grahnén; M Hammarlund; T Lundqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): a new angiotensin-converting enzyme inhibitor.

Authors:  G T Griffing; B H Sindler; S A Aurecchia; J C Melby
Journal:  Metabolism       Date:  1983-07       Impact factor: 8.694

View more
  10 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 4.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

5.  Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects.

Authors:  A Fujimura; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Interference of different ACE-inhibitors with the diuretic action of furosemide and hydrochlorothiazide.

Authors:  C Toussaint; A Masselink; A Gentges; G Wambach; G Bönner
Journal:  Klin Wochenschr       Date:  1989-11-17

7.  Effects of angiotensin-converting enzyme inhibition on renal sodium handling after furosemide injection.

Authors:  R Nowack; D Fliser; J Richter; C Horne; E Mutschler; E Ritz
Journal:  Clin Investig       Date:  1993-08

Review 8.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 9.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 10.  Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.

Authors:  M Burnier; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.